Rupert c thomas (14 Ergebnisse)

Zustand: Fair. 1942. No Edition Remarks. 143 pages. No dust jacket. Blue cloth boards with lettering. Clean pages with light tanning and mild foxing throughout. More pronounced to free endpapers and pastedowns. Binding remains firm. Boards have mild edge-wear with slight rubbing to surfaces and bumping to corners. Lettering is darkened. Visible wear marks to boards.…

Zustand: Gebraucht - Sehr gut. SPRINGER VERLAG - 2011 - H4.

A pamphlet produced to counter arguments against British-Israel philosophy. 40pp. a near very good copy in paper covers.

War-time British-Israel prophecy of a New Age.143pp. Some scant foxing, slight fading to top of spine but o/w agood++ hardback copy in blue cloth binding in worn dustcover.

British-Israel material. 143pp. some slight rubbing to top edges of covers, light foxing to epps., but o/w a very good hardback copy in blue cloth binding. Fed.stamp to fep.

64pp. Stiff card covers inside wraps. Very good.

Zustand: New. In English.

Zustand: New. In English.

Taschenbuch. Zustand: Neu. Drugs for HER-2-positive Breast Cancer | Maria Sibilia (u. a.) | Taschenbuch | Milestones in Drug Therapy | x | Englisch | 2013 | Springer | EAN 9783034803182 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu. …

Paperback. Zustand: Brand New. 2011 edition. 119 pages. 9.25x6.10x0.28 inches. In Stock.

Hardcover. Zustand: Brand New. 1st edition. 110 pages. 9.25x6.50x0.50 inches. In Stock.

Zustand: New. Growth factor receptors have long been known to drive malignant transformation and cancer progression. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Thsi book deals with this topic. Editor(s): Zielinski, Christoph C.; Sibilia, Maria; Bergen, Elisabeth; Grunt, Thomas W.; Bartsch, Rupert. Series: Milestones in Drug Therapy. Num Pages: 120 pages, biography. BIC Classification: MJCL; MJCM; MMG. Category: (P) Professional & Vocational. Dimension: 244 x 164 x 14. Weight in Grams: 384. . 2011. Hardback. . . . . Books ship from the US and Ireland.…

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.…

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.…